History

2012: A new rights issue was completed in April 2012. It was over-subscribed by approximately 3.3 MSEK, excluding commited warranties. Through the rights issue the company has been issued 3 852 770 shares and 1 926 385 warrants of the series TO 1. AroCell added thus approximately 5.2 MSEK in fresh capital before issue costs.

A collaboration with the American company GenScript Inc. was started for development of new improved antibodies with a new methodology. The new antibodies will replace the component in AroCell´s product that showed variability in the production. AroCell will use this method to select exactly the new antibodies that are best suited for AroCells future products.

2011: A new share issue was completed in May 2011 of 7 MSEK. The proceeds are used for final development, production set up and launch of  first product, TK 210/hem. After completion of the issue the company was listed on AktieTorget ( EquitY Marketplace).

A distribution agreement for Italy was signed with the Italian company BIO EXE S.r.l. in November 2011.

2010: A rights issue of totally 2.6 MSEK was finalized in June 2010.The money will cover the costs for the final development phase and basic clinical documentation of the ELISA test.

An agreement was signed between AroCell and EuroDiagnostica in July 2010 for production of the TK
ELISA.

2009: Third round of investments, April 2009, for the first step in the development of a clinically usefull TK ELISA.

2008: Prototype ELISA assay developed.

2007: Introducing our first product for immunohistochemistry and prototype ELISA assay. The first product based on our patented cell proliferation marker XPA-210 is now availabe for customers in immunohistochemistry. Find more information here, under “Products & technology / Immunohistochemistry”.
Please visit our distributor at: www.immunsystem.com to place an order (webpage will be updated with our products).

2006: Changes name to AroCell AB.

2006: Eureka project acceptance and funding from Vinnova.

2006: Prize winning in Venture Cup, (2nd and 3rd stage). Finalist in “Swedish Spin-off Company of the year” (Årets avknoppningsföretag, February 2007). AroCell was named one of six finalists in the annual award.

2005: First financing.

2003: Founded as “Xi Bao Research AB” by Per Matsson (Phadia AB), Qimin He, Sven Skog and Bernhard Tribukait (Karolinska Institute), Arne Ferstad (external consultant) and Staffan Eriksson (Swedish University of Agricultural Sciences).

1995: Patent application for new tumor marker (patents granted 2000 and 2001).